Clinical Trial

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).
Protocol Amendment History 3 changes
notable Trial sites expanded: 57 -> 62 locations 2026-05-23
notable Trial sites expanded: 50 -> 57 locations 2026-05-09
notable Trial sites expanded: 23 -> 50 locations 2026-04-25
Trial Details
NCT Number NCT07277660
Lead Sponsor UCB Biopharma SRL
Conditions Atopic Dermatitis
Enrollment 160 participants
Start Date 2025-12-29
Primary Completion 2027-05-17 (estimated)
Study Completion 2028-03-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-14